Drugs / DENRAKIBART
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05174013 | Feb 2022 → Feb 2023 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT04114656 | Oct 2019 → Sep 2021 | — | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT03485365 | May 2018 → Sep 2022 | inflammatory disease | GlaxoSmithKline | Completed | Mixed |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT05838755 | Sep 2023 → Oct 2024 | — | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT05838742 | Sep 2023 → Aug 2024 | osteoarthritis, knee | GlaxoSmithKline | Terminated | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DENRAKIBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068232 ↗ |
| Known as | GSK3858279 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05838742 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068232 ↗ |
| Route | Intravenous | “GSK3858279 will be available as solution for injection to be administered via IV route.” NCT03485365 ↗ |